ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty Opinions recommendation of Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.728641380.793535529
◽
2017
◽
Author(s):
Bryan Anderson
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Targeted Approach
Download Full-text
Related Documents
Cited By
References
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management
Future Oncology
◽
10.2217/fon-2017-0263
◽
2017
◽
Vol 13
(27)
◽
pp. 2405-2411
◽
Cited By ~ 9
Author(s):
Julia J Scarisbrick
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Targeted Approach
Download Full-text
Alternate dosing regimens of brentuximab vedotin for CD 30+ cutaneous T‐cell lymphoma
British Journal of Dermatology
◽
10.1111/bjd.15970
◽
2018
◽
Vol 178
(1)
◽
pp. 302-303
◽
Cited By ~ 2
Author(s):
D.J. Lewis
◽
Y.H. Kim
◽
M. Duvic
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Dosing Regimens
Download Full-text
Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicenter European EORTC study
European Journal of Cancer
◽
10.1016/s0959-8049(19)30604-5
◽
2019
◽
Vol 119
◽
pp. S34-S35
Author(s):
E. Papadavid
◽
V. Pappa
◽
E. Kapniari
◽
V. Nikolaou
◽
T. Hliakis
◽
...
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Real Life
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Life Data
◽
Real Life Data
Download Full-text
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet
◽
10.1016/s0140-6736(17)31266-7
◽
2017
◽
Vol 390
(10094)
◽
pp. 555-566
◽
Cited By ~ 209
Author(s):
H Miles Prince
◽
Youn H Kim
◽
Steven M Horwitz
◽
Reinhard Dummer
◽
Julia Scarisbrick
◽
...
Keyword(s):
T Cell
◽
Multicentre Trial
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Open Label
◽
Phase 3
Download Full-text
Our first experiences with brentuximab vedotin in the treatment of cutaneous T-cell lymphoma
Bőrgyógyászati és Venerológiai Szemle
◽
10.7188/bvsz.2019.95.3.8
◽
2019
◽
Vol 95
(3)
◽
pp. 129-135
Author(s):
József Szakonyi
◽
◽
Veronika Tóth
◽
Béla Tóth
◽
Ágota Szepesi
◽
...
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
Download Full-text
Real‐world effectiveness of brentuximab vedotin in the treatment of CD30‐positive cutaneous T‐cell lymphoma: A single‐centre retrospective review
British Journal of Dermatology
◽
10.1111/bjd.20786
◽
2021
◽
Author(s):
M.‐H. Henderson Berg
◽
K. Davison
◽
G. Popradi
Keyword(s):
T Cell
◽
Real World
◽
Retrospective Review
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Single Centre
Download Full-text
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)
Hematological Oncology
◽
10.1002/hon.96_2630
◽
2019
◽
Vol 37
◽
pp. 286-288
◽
Cited By ~ 1
Author(s):
S.M. Horwitz
◽
J. Scarisbrick
◽
H.M. Prince
◽
S. Whittaker
◽
M. Duvic
◽
...
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Phase 3
◽
Final Data
Download Full-text
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
Current Hematologic Malignancy Reports
◽
10.1007/s11899-020-00561-w
◽
2020
◽
Vol 15
(1)
◽
pp. 9-19
Author(s):
Lauren Shea
◽
Neha Mehta-Shah
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Peripheral T Cell Lymphoma
Download Full-text
RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY
Hematological Oncology
◽
10.1002/hon.2438_109
◽
2017
◽
Vol 35
◽
pp. 245-247
Author(s):
S. Horwitz
◽
S. Whittaker
◽
M. Duvic
◽
R. Dummer
◽
Y.H. Kim
◽
...
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Phase 3
Download Full-text
Alternate dosing regimens of brentuximab vedotin for CD 30+ cutaneous T‐cell lymphoma: reply from the authors
British Journal of Dermatology
◽
10.1111/bjd.15972
◽
2017
◽
Vol 178
(1)
◽
pp. 303-303
Author(s):
R. Stranzenbach
◽
E. Dippel
◽
M. Schlaak
◽
R. Stadler
Keyword(s):
T Cell
◽
Cell Lymphoma
◽
Brentuximab Vedotin
◽
T Cell Lymphoma
◽
Cutaneous T Cell Lymphoma
◽
Dosing Regimens
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close